XTANDI is a prescription medicine used to treat men with prostate cancer that:

  • no longer responds to a hormone therapy or surgical treatment to lower testosterone
  • OR

  • has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone

It is not known if XTANDI is safe and effective in females or children.

Pay as little as
$0 per month.

See if you're eligible >

It's all about
having a game
plan

XTANDI was proven to help men with advanced prostate cancer delay progression and live longer

Proven results in 3 types of advanced prostate cancer

Metastatic castration-sensitive prostate cancer (mCSPC)

Prostate cancer that has spread and still responds to treatment to lower testosterone

61%
LOWER
CHANCE

In a study with 1,150 men, XTANDI lowered the chance of progression by 61%.

The median* length of time until the cancer got worse was not reached for XTANDI + ADT** vs. 19 months for ADT alone.

Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.

In this same study, XTANDI helped men live longer.
XTANDI significantly improved overall survival by 34% vs ADT alone.

The median length of time patients lived after starting treatment was not reached.

Metastatic castration-resistant prostate cancer (mCRPC)

Prostate cancer that has spread and no longer responds to hormone therapy or surgical treatment to lower testosterone

83%
LOWER
CHANCE

In a study with 1,717 men, XTANDI lowered the chance of progression by 83%.

The median length of time until the cancer got worse was not reached for XTANDI + ADT vs. 4 months for ADT alone.

Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.

In this same study, XTANDI helped men live longer. The median overall survival was 35 months for men taking XTANDI + ADT vs. 31 months for ADT alone.

Non-metastatic castration-resistant prostate cancer (nmCRPC)

Prostate cancer that has not spread and no longer responds to hormone therapy or surgical treatment to lower testosterone

71%
LOWER
CHANCE

In a study with 1,401 men, XTANDI lowered the chance of progression by 71%.

The median length of time until the cancer spread was 37 months for XTANDI + ADT vs. 15 months for ADT alone.

Progression was defined as the cancer spreading, as measured by scans, or if the patient died for any reason.

In this same study, XTANDI helped men live longer. The median overall survival was 67 months for men taking XTANDI + ADT vs. 56 months for ADT alone.

Results may vary. Talk with your doctor about what this may mean for you.

*The median is not the average but the middle of a set of numbers.

**ADT= Androgen Deprivation Therapy.

Select Safety Information

XTANDI may cause serious side effects, including seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure.

#1 prescribed branded novel hormone therapy
for advanced prostate cancer by oncologists and urologists.

Based on IQVIA NBRx rolling 4-week data, February 2021-January 2022.
THIS INFORMATION DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. NO COMPARISONS SHOULD BE MADE.

Since FDA approval in 2012, 209,000 patients have been prescribed XTANDI

People icon
  Estimate based on US sales and use data from September 2012 to June 2021. Reference: Astellas. XTANDI data on file.

Create a Game Plan with Your Doctor

Use this Doctor Discussion Guide for help with questions you may want to ask your doctor at your next visit.

Create a Game Plan with Your Doctor

Tablet showing XTANDI® (enzalutamide) Doctor Discussion Guide Tablet showing XTANDI® (enzalutamide) Doctor Discussion Guide

Real Patient Stories

“I can’t stress enough how important it is to be your own advocate. I talked to my doctor, and we worked together to get XTANDI approved by my insurance company.”

— Mahlon, an XTANDI patient.

Real Patient Stories

This shows bottom of video container

Copay Assistance for Commercially Insured Patients

The XTANDI Patient Savings Program* is for eligible patients who have commercial prescription insurance.

XTANDI® (enzalutamide) Copay Card
XTANDI® (enzalutamide) Copay Card

Copay Assistance for Commercially Insured Patients

The XTANDI Patient Savings Program* is for eligible patients who have commercial prescription insurance.

*By enrolling in the XTANDI Patient Savings Program ("Program"), you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions: The Program is for eligible patients with commercial prescription insurance for XTANDI. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who move from commercial insurance to federal or state health insurance will no longer be eligible, and agree to notify the Program of any such change. Patients agree not to seek reimbursement from any health insurance or third party for all or any part of the benefit received by the patient through the Program. This offer is not conditioned on any past, present, or future purchase of XTANDI. This offer is not transferrable and cannot be combined with any other offer, free trial, prescription savings card, or discount. This offer is not health insurance and is only valid for patients in the 50 United States, Washington DC, Puerto Rico, Guam and Virgin Islands. This offer is not valid for cash paying patients. This Program is void where prohibited by law. No membership fees. It is illegal to sell, purchase, trade, counterfeit, duplicate, or reproduce, or offer to sell, purchase, trade, counterfeit, duplicate, or reproduce the card. This offer will be accepted only at participating pharmacies. Certain rules and restrictions apply. Astellas reserves the right to revoke, rescind, or amend this offer without notice.

You are now leaving XTANDI.com

The website you are about to visit is not owned or controlled by Astellas or Pfizer. Astellas and Pfizer are not responsible for the information or services on this site.

You are now leaving XTANDI.com

Please verify that you are a U.S. Healthcare Professional.

This information is intended for U.S. Healthcare Professionals only.

Are you a U.S. Healthcare Professional?